The Clinical Trials Program at the ESRF Biomedical Beamline ID17: Status and Remaining Steps

摘要: For several years the ID17 Biomedical beamline at ESRF has developed synchrotron radiation therapy preclinical programmes to treat aggressive brain tumours. Two techniques have been ESRF:a) The Microbeam Radiation Therapy (MRT) using spatially fractionated “white beam” (energies 50–300 keV) irradiation (beam widths 25–100 μm, spacing between beams 200–400 μm ) with extremely high dose rates (up about 20 kGy/s) and depositing very doses (300–1000 Gy) in targeted tissue.b) Stereotactic Synchrotron (SSRT) homogeneous monochromatic beam energy closely above that of K‐edge a contrast‐ or chemotherapeutical agent (iodine, gadolinium, platinum) loaded into tumour volume for obtaining dose‐enhancement.In 2005 an International review panel oncology experts recommended move clinical trials on humans SSRT large animals MRT. works required this program were launched autumn 2007 constr...